PATHEON N.V.
PATHEON N.V. (PTI): 3 pipeline candidates · ~12 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
11.9 months
1% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for PATHEON N.V.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$92.7M
Quarterly Burn
$92.5M
Runway
11.9 mo
Revenue
$483.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in PATHEON N.V.'s pipeline?
PATHEON N.V. (PTI) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PATHEON N.V.'s lead drug candidate?
PATHEON N.V.'s most advanced tracked candidate is ibuprofen (Approved) for Uses temporarily relieves minor aches and pains due to: headache toothache backache menstrual cramps the common cold muscular aches minor pain of arthritis temporarily reduces fever.
What is PATHEON N.V.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PATHEON N.V. has approximately 11.9 months of cash runway.
Who is the CEO of PATHEON N.V.?
James C. Mullen is the chief executive officer of PATHEON N.V. (PTI).
Get the full picture on PATHEON N.V.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.